Loading articles...
MAVEs Inform Variant Interpretation in Clinical Oncology Practice
Multiplex Assays of Variant Effects (MAVEs) offer a systematic approach to interpreting genetic variants in oncology, addressing current limitations in variant classification.
AI in Oncology: Practical Applications Transforming Cancer Care
AI integration in oncology is moving beyond theoretical promise to deliver tangible benefits in diagnosis, treatment planning, and patient management.
HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026
Understanding tumor evolution is critical for effective cancer therapy. The Human Tumor Atlas Network (HTAN) provides an ecological and evolutionary framework.
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
Extracellular vesicles (EVs) and particles (EPs) offer new avenues for cancer diagnosis, prognosis, and therapy. Their role as biomarkers and drug delivery systems is expanding.
NK Cell Immunotherapy: Biology to Clinic at AACR 2026
Natural killer (NK) cell-based immunotherapies are emerging as a promising cancer treatment strategy, with ongoing clinical trials exploring their efficacy.
Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review
Cancer therapies, while life-saving, induce significant long-term comorbidities across all age groups, necessitating integrated survivorship care.
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
The pipeline for pediatric oncology drugs remains sparse, with most candidates failing to progress beyond early-phase trials to approval.